Literature DB >> 8749638

Serum therapy for Cryptococcal meningitis.

M A Gordon1, A Casadevall.   

Abstract

Three patients were treated with combined amphotericin B and rabbit anticryptococcal antibody in the 1960s. Rabbit antibody was administered intravenously and was well tolerated. For each patient, administration of rabbit antibody resulted in the appearance of serum Cryptococcus neoformans agglutinins. For two patients the administration of rabbit antibody resulted in negative serum latex tests for cryptococcal antigen. This limited experience with adjunctive antibody therapy provides valuable precedents if antibody therapy is used again for treatment of human cryptococcosis.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8749638     DOI： 10.1093/clinids/21.6.1477

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

2.  Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.

Authors:  Robert A Larsen; Peter G Pappas; John Perfect; Judith A Aberg; Arturo Casadevall; Gretchen A Cloud; Robert James; Scott Filler; William E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation.

Authors:  A Vecchiarelli; C Retini; C Monari; A Casadevall
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

4.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 5.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.